In this context, CebpaDM AML cells gain a competitive advantage by loss of TET2, which in turn promotes an increase in DNA methylation at the Gata2 promoter resulting in the rebalancing of Gata2 levels. This evidence concerns the gene GATA2 and acute myeloid leukemia.